Kiora Pharmaceuticals, Inc. announced preclinical data demonstrating that its ion channel modulator platform significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. The findings were presented at the Epilepsy Foundation Pipeline Conference in Leesburg, VA. Kiora Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapies for epilepsy and other neurological disorders.

At its 2026 annual meeting held on June 10, 2026, Kiora Pharmaceuticals, Inc. stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the number of common shares available for issuance by 1,500,000. Additionally, shareholders elected Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D. as Class II Directors for three-year terms. The meeting also resulted in the non-binding approval of executive compensation, the ratification of Haskell & White LLP as the independent auditor for the 2026 fiscal year, and the approval of the aforementioned equity plan amendment. Kiora Pharmaceuticals is a pharmaceutical company.